Health
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
DENVER, March 26, 2026--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Pha
About this update from Almirall Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/d2c9dbfea6f2b15b39f205e10f7a1a03"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T3gmwrBsmGfWaqzklZi68A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMA--/https://media.zenfs.com/en/business-wire.com/d2c9dbfea6f2b15b39f205e10f7a1a03","width":480,"height":210}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Almirall advances scientific leadership in medical dermatology with new data across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcomes.","length":199,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"More than 15 posters will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, including 9 on lebrikizumab, new analyses for tirbanibulin, two on tildrakizumab showing the final 2 year results of the POSITIVE study on patient wellbeing, and new results and analysis for sarecycline.","length":308,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":507,"olType":false},{"type":"text","content":"DENVER, March 26, 2026--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Phase 3 evaluations in acne.","length":542,"tagName":"p"},{"type":"text","content":""Our goal is to bring meaningful, evidence‑based treatment options to people living with skin diseases. The breadth of data we are sharing at AAD 2026 – from long‑term results and real‑world evidence for lebrikizumab to clinically relevant AK endpoints with tirbanibulin – reflects our commitment to rigorous science, patient‑centred outcomes, and strong collaboration with dermatology partners," said Dr. Volker Koscielny, Almirall’s Chief Medical Officer.","length":467,"tagName":"p"},{"type":"text","content...